Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...
Johnson & Johnson's Spravato has become the first standalone drug to be cleared by the FDA for adults with treatment-resistant depression. Join the conversation, on Tuesday 28th January @ 10 am ET ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback